凡德他尼
卡波扎尼布
甲状腺髓样癌
医学
不利影响
酪氨酸激酶抑制剂
肿瘤科
癌症
内科学
甲状腺癌
酪氨酸激酶
受体
作者
Linnea Højer Wang,Markus Wehland,Petra Wise,Manfred Infanger,Daniela Grimm,Michael C. Kreißl
摘要
This manuscript investigates cabozantinib, vandetanib, pralsetinib, and selpercatinib, four tyrosine kinase inhibitors (TKIs), which are used to treat advanced and/or metastatic medullary thyroid cancer (MTC). Data on efficacy and safety are presented with the main focus on treatment-related hypertension, a well-known adverse effect (AE) of these TKIs. Taken together, TKI-induced hypertension is rarely a dose-limiting side effect. However, with increasing survival times of patients under treatment, hypertension-associated complications can be expected to be on the rise without proper medication.
科研通智能强力驱动
Strongly Powered by AbleSci AI